Lupin Limited · NSE:LUPIN
Lupin — Q1 FY2022 Earnings Presentation
14 slides from Lupin's earnings presentation, Aug 11, 2021
Slide 1: Exchange cover letter for Q1 FY2022 Investor Presentation
Aug ust 11, 2021 BSE Limited Department of Corporate Services, P. J. Tow ers, Dalal Street MUMBAI - 400 001. .; National Stock Exchange of India Limited Excha nge Plaza, Bandra Kurio Complex, Ba ndra (East) , Mumbai - 400 051 . Dear Sir/Madam, Sub: Ql FY2022 Investor Presentation. Pursuant to Regula
Slide 2: Investor Presentation Q1 FY2022
Investor Presentation Q1 FY2022 August 11, 2021
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to diffe
Slide 4: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta named among Most Powerful Women in Business in India – #7 by Fortune India • India Pharma Leader Award - India Pharma 2020 and India Medical Device 2020 conference organized by FICCI and the Ministry of Chemicals and Fertilizers, GOI • Lupin ranked No.1 in
Slide 5: Q1 FY2022 Snapshot
Q1 FY2022 Snapshot Important developments Sales (INR mn, YoY Growth) Commercial Mr. Nilesh.D.Gupta • Acquisition of Southern Cross Pharma in Australia, India, North America, Managing Director Lupin Limited gaining access to over 60 registered products having 16,362, 27% 13,330, 10% sales of over AU$
Slide 6: Strategic Vision
Strategic Vision Well Diversified Pharma Company Integrated Global Quality Culture Novel products North America NaMuscla Novel Oncology Women’s Health Franchise Research Platform Committed to building Capability building and Geographic expansion Pipeline acceleration robust specialty portfolio expan
Slide 7: Q1 FY22 Financial Results Review
Q1 FY22 Financial Results Review
Slide 8: P&L Highlights – Q1 FY2022
P&L Highlights – Q1 FY2022 % of % of QoQ % of YoY Amount in INR mn Q1 FY22 Q4 FY21 Q1 FY21 sales sales growth sales growth Net sales 42,374 100.0% 37,593 100.0% 12.7% 34,686 100.0% 22.2% Other operating income 328 238 593 Total revenue 42,702 37,831 12.9% 35,279 21.0% Gross profit 27,094 63.9% 24,41
Slide 9: North America
Q1FY22 North America 35% YoY 9.6% QoQ 10.8% Competitive pressures witnessed in specific products Consolidating our position in the US1 US quarterly sales (US$ mn) #3 #3 #3 #3 140 #4 #4 6 188 195 120 180 172 #5 129 5 157 29.4% average 100 123 121 120 109 4 market share2 80 83 3 60 79 40 65 63 2 51 53
Slide 10: India
Q1FY22 India 42% YoY 27.3% QoQ 27.2% Robust India business performance Consistently outpacing chronic market growth India quarterly Sales (INR bn) 5 Year CAGR % Lupin Rank1 16.4 MAT MAT Therapy Market Lupin 13.7 Jun-16 Jun-21 12.9 13.3 12.9 Acute 9% 6% 13 15 Chronic 11% 15% 5 4 Cardiac 11% 12% 3 3 A
Slide 11: Other Markets
Other Markets • Germany: EUR 7.4 mn sales in Q1 FY22 EU5 • UK: gFostair launch preparations on track Developed • 4th largest generics player1 Australia • Acquisition of Southern Cross Pharma to significantly increase value proposition and market share in the Australian market • 5th largest Rx generi
Slide 12: Key Financial Metrics
Key Financial Metrics R&D (INR million) Capex (INR million) 3,843 3,737 1,793 1,905 3,575 3,479 3,427 1,396 1,182 1,057 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 1 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 R&D (% of sales) Net debt/ Equity 0.13 10.3% 10.2% 8.9% 9.1% 8.8% 0.10 0.05 0.03 (0.02) Q1FY21 Q2FY21 Q3FY21
Slide 13: Manufacturing and R&D – Diverse Global Network
Manufacturing and R&D – Diverse Global Network Global Commercial Presence 100 23 13 Countries where Countries with Countries with OPERATIONS products are sold marketing offices subsidiaries RESEARCH 15 7 Manufacturing Sites R&D Sites ◼ 13 U.S.FDA inspected units ◼ 440 US ANDAs; 291 approved ◼ 30 bn+
Slide 14: Thank you
Thank you Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway Santacruz (East), Mumbai 400 055, India. www.lupin.com www.twitter.com/LupinGlobal www.linkedin.com/company/lupin/ www.facebook.com/LupinWorld/ Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051